Predicting the clinical outcome of stimulant medication in pediatric attention-deficit/hyperactivity disorder: Data from quantitative electroencephalography, event-related potentials, and a go/no-go test

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 231-242

  Ogrim, Geir ^a,b,c   Kropotov, Juri ^c,d,e   Brunner, Jan Ferenc ^c,f   Candrian, Gian ^g   Sandvik, Leiv ^h   Hestad, Knut A ^c,i  

^a Østfold Hospital Trust   (Norway)

^b National Centre for AD/HD   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d Institute of the Human Brain Russian Academy of Sciences   (Russian Federation)

^e ANDRZEJ FRYCZ MODRZEWSKI KRAKOW UNIVERSITY   (Poland)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g Organisation und Entwicklung   (Switzerland)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

ADHD; Clinical outcome; ERP; Go no go test; Predictions; QEEG; Stimulants

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ALPHA RHYTHM; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BETA RHYTHM; CHILD; COMMISSION ERROR; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; EFFECT SIZE; ELECTROENCEPHALOGRAPHY; ERROR; EVENT RELATED POTENTIAL; FEMALE; GO NO GO TEST; HUMAN; INTELLIGENCE QUOTIENT; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; OCCIPITAL CORTEX; OMISSION ERROR; OUTCOME ASSESSMENT; PARIETAL CORTEX; PREDICTIVE VALUE; PREFRONTAL CORTEX; REACTION TIME; THETA RHYTHM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84893530212     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S56600     Document Type: Article

References (89)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Polanczyk G, Jensen P. Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc Psychiatr Clin N Am. 2008;17(2):245-260.
4. Barkley RA, editor. Attention-Deficit Hyperactivity Disorder A Handbook for Diagnosis and Treatment. 3rd ed. New York: The Guilford Press; 2006.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013.
6. Gillberg C, Gillberg IC, Rasmussen P, etal. Co-existing disorders in ADHD: implications for diagnosis and intervention. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I80-I92.
7. Zeiner P, Bryhn G, Bjercke C, Truyen K, Strand G. Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatr. 1999;88(3):298-303.
8. Tannock R, Schachar RJ, Carr RP, Chajczyk D, Logan GD. Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol. 1989;17(5):473-491.
9. Schweitzer JB, Lee DO, Hanford RB, etal. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry. 2004;56(8):597-606.
10. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2006;30(8):1225-1245. doi: 10.1016/j.neubiorev.2006.10.002.
11. Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry. 2011;11:70.
12. Solanto MV. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res. 2002;130(1-2):65-71.
13. Berridge CW, Devilbiss DM, Andrzejewski ME, etal. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60(10):1111-1120.
14. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4): 409-432.
15. Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E. Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. J Integr Neurosci. 2005;4(1):107-121.
16. Nigg JT. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry. 2005;57(11):1424-1435.
17. Ramtvedt BE, Roinas E, Aabech HS, Sundet KS. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. J Child Adolesc Psychopharmacol. 2013;23(9):597-604.
18. Hale JB, Reddy LA, Semrud-Clikeman M, etal. Executive impairment determines ADHD medication response: implications for academic achievement. J Learn Disabil. 2011;44(2):196-212.
19. Sangal RB, Sangal JM. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. Clin Neurophysiol. 2006;117(9):1996-2006.
20. Loo SK, Makeig S. Clinical utility of EEG in attention-deficit/hyperactivity disorder: a research update. Neurotherapeutics. 2012;9(3): 569-587.
21. Ogrim G, Kropotov J, Hestad K. The quantitative EEG theta/beta ratio in attention deficit/hyperactivity disorder and normal controls: sensitivity, specificity, and behavioral correlates. Psychiatry Res. 2012;198(3):482-488.
22. Arns M, Conners CK, Kraemer HC. A decade of EEG theta/beta ratio research in ADHD: a meta-analysis. J Atten Disord. 2013;17(5): 374-383.
23. Barry RJ, Clarke AR, Johnstone SJ. A review of electrophysiology in attention-deficit/hyperactivity disorder: I. qualitative and quantitative electroencephalography. Clin Neurophysiol. 2003;114(2):171-183.
24. Clarke AR, Barry RJ, McCarthy R, Selikowitz M. EEG-defined subtypes of children with attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2001;112(11):2098-2105.
25. Clarke AR, Barry RJ, McCarthy R, Selikowitz M. Excess beta activity in children with attention-deficit/hyperactivity disorder: an atypical electrophysiological group. Psychiatry Res. 2001;103(2-3):205-218.
26. Dupuy FE, Clarke AR, Barry RJ, McCarthy R, Selikowitz M. EEG coherence in girls with attention-deficit/hyperactivity disorder: stimulant effects in good responders. Int J Psychophysiol. 2008;70(3):151-157.
27. Liechti MD, Valko L, Muller UC, etal. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. Brain Topogr. 2012;26(1):135-151.
28. Chabot RJ, Serfontein G. Quantitative electroencephalographic profiles of children with attention deficit disorder. Biol Psychiatry. 1996;40(10):951-963.
29. Loo SK, Barkley RA. Clinical utility of EEG in attention deficit hyperactivity disorder. Appl Neuropsychol. 2005;12(2):64-76.
30. Bresnahan SM, Barry RJ, Clarke AR, Johnstone SJ. Quantitative EEG analysis in dexamphetamine-responsive adults with attention-deficit/hyperactivity disorder. Psychiatry Res. 2006;141(2):151-159.
31. Arns M, Gunkelman J, Breteler M, Spronk D. EEG phenotypes predict treatment outcome to stimulants in children with ADHD. J Integr Neurosci. 2008;7(3):421-438.
32. Clarke AR, Barry RJ, Bond D, McCarthy R, Selikowitz M. Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2002;164(3): 277-284.
33. Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Brown CR, Croft RJ. Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder predominantly inattentive type. Int J Psychophysiol. 2003;47(2):129-137.
34. Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Johnstone SJ. Effects of stimulant medications on the EEG of girls with attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2007;118(12):2700-2708.
35. Clarke AR, Barry RJ, McCarthy R, etal. Effects of methylphenidate on EEG coherence in attention-deficit/hyperactivity disorder. Int J Psychophysiol. 2005;58(1):4-11.
36. Chabot RJ, Orgill AA, Crawford G, Harris MJ, Serfontein G. Behavioral and electrophysiologic predictors of treatment response to stimulants in children with attention disorders. J Child Neurol. 1999;14(6): 343-351.
37. Lubar JF, White JN Jr, Swartwood MO, Swartwood JN. Methylphenidate effects on global and complex measures of EEG. Pediatr Neurol. 1999;21(3):633-637.
38. Song DH, Shin DW, Jon DI, Ha EH. Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test. Yonsei Med J. 2005;46(1):34-41.
39. Suffin SC, Emory WH. Neurometric subgroups in attentional and affective disorders and their association with pharmacotherapeutic outcome. Clin Electroencephalogr. 1995;26(2):76-83.
40. Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Croft RJ. EEG differences between good and poor responders to methylphenidate in boys with the inattentive type of attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2002;113(8):1191-1198.
41. Saletu B, Anderer P, Saletu-Zyhlarz GM. EEG topography and tomography (LORETA) in the classification and evaluation of the pharmacodynamics of psychotropic drugs. Clin EEG Neurosci. 2006;37(2): 66-80.
42. Mucci A, Volpe U, Merlotti E, Bucci P, Galderisi S. Pharmaco-EEG in psychiatry. Clin EEG Neurosci. 2006;37(2):81-98.
43. Loo SK, Hopfer C, Teale PD, Reite ML. EEG correlates of methylphenidate response in ADHD: association with cognitive and behavioral measures. J Clin Neurophysiol. 2004;21(6):457-464.
44. Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Clarke DC, Croft RJ. Effects of stimulant medications on children with attention-deficit/hyperactivity disorder and excessive beta activity in their EEG. Clin Neurophysiol. 2003;114(9):1729-1737.
45. Broyd SJ, Johnstone SJ, Barry RJ, etal. The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder. Int J Psychophysiol. 2005;58(1): 47-58.
46. Sangal RB, Sangal JM. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate. Clin Neurophysiol. 2004;115(1):188-193.
47. Falkenstein M, Hoormann J, Hohnsbein J. ERP components in go/nogo tasks and their relation to inhibition. Acta Psychol (Amst). 1999;101(2-3):267-291.
48. Polich J. Neuropsychology of P300. In: Luck SJ, Kappenmann E, editors. The Oxford Handbook of Event-Related Potentials Components. 1st ed. Oxford, UK: Oxford University Press; 2012:159-187.
49. Spronk M, Jonkman LM, Kemner C. Response inhibition and attention processing in 5-to 7-year-old children with and without symptoms of ADHD: an ERP study. Clin Neurophysiol. 2008;119(12):2738-2752.
50. Doehnert M, Brandeis D, Imhof K, Drechsler R, Steinhausen HC. Mapping attention-deficit/hyperactivity disorder from childhood to adolescence: no neurophysiologic evidence for a developmental lag of attention but some for inhibition. Biol Psychiatry. 2010;67(7):608-616.
51. van Rijn H, Kononowicz TW, Meck WH, Ng KK, Penney TB. Contingent negative variation and its relation to time estimation: a theoretical evaluation. Front Integr Neurosci. 2011;5:91.
52. Brunia CHM, van Boxtel GJM, Böcker KBE. Negative slow waves as indices of anticipation. In: Luck SJ, Kappermann ES, editors. The Oxford Handbook of Event-Related Potentional Components. 1st ed. Oxford, UK: Oxford University Press; 2012:189-208.
53. Ansari TL, Derakshan N. The neural correlates of cognitive effort in anxiety: effects on processing efficiency. Biol Psychol. 2011;86(3): 337-348.
54. Kappenman ES, Luck SJ. ERP components: the ups and downs of brainwave recordings. In: Luck SJ, Kappenman ES, editors. The Oxford Handbook of Event-Related Potential Components. 1st ed. Oxford, UK: Oxford University Press; 2012:3-29.
55. Brunner JF, Hansen TI, Olsen A, Skandsen T, Håberg A, Kropotov J. Long-term test-retest reliability of the P3 NoGo wave and two independent components decomposed from the P3 NoGo wave in a visual Go/NoGo task. Int J Psychophysiol. 2013;89(1):106-114.
56. Kropotov JD, Ponomarev VA, Hollup S, Mueller A. Dissociating action inhibition, conflict monitoring and sensory mismatch into independent components of event related potentials in GO/NOGO task. Neuroimage. 2011;57(2):565-575.
57. Brandeis D, Banaschewski T, Baving L, etal. Multicenter P300 brain mapping of impaired attention to cues in hyperkinetic children. J Am Acad Child Adolesc Psychiatry. 2002;41(8):990-998.
58. Wiersema JR, Roeyers H. ERP correlates of effortful control in children with varying levels of ADHD symptoms. J Abnorm Child Psychol. 2009;37(3):327-336.
59. Johnstone SJ, Barry RJ, Clarke AR. Ten years on: a follow-up review of ERP research in attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2013;124(4):644-657.
60. Mueller A, Candrian G, Kropotov JD, Ponomarev VA, Baschera GM. Classification of ADHD patients on the basis of independent ERP components using a machine learning system. Nonlinear Biomed Phys. 2010;4 Suppl 1:S1.
61. Doehnert M, Brandeis D, Schneider G, Drechsler R, Steinhausen HC. A neurophysiological marker of impaired preparation in an 11-year follow-up study of attention-deficit/hyperactivity disorder (ADHD). J Child Psychol Psychiatry. 2013;54(3):260-270.
62. Sawada M, Iida J, Ota T, etal. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials. Psychiatry Clin Neurosci. 2010;64(5):491-498.
63. Sangal RB, Sangal JM. Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment. Expert Rev Neurother. 2006;6(10):1429-1437.
64. Idiazabal-Alecha MA, Rodriguez-Vazquez S, Guerrero-Gallo D, Vicent-Sardinero X. The value of cognitive evoked potentials in assessing the effectiveness of methylphenidate treatment in children with attention deficit hyperactivity disorder. Rev Neurol. 2005;40 Suppl 1:S37-S42.
65. Sunohara GA, Voros JG, Malone MA, Taylor MJ. Effects of methylphenidate in children with attention deficit hyperactivity disorder: a comparison of event-related potentials between medication responders and non-responders. Int J Psychophysiol. 1997;27(1):9-14.
66. Sunohara GA, Malone MA, Rovet J, Humphries T, Roberts W, Taylor MJ. Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence. Neuropsychopharmacology. 1999;21(2):218-228.
67. Groom MJ, Scerif G, Liddle PF, etal. Effects of motivation and medication on electrophysiological markers of response inhibition in children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2010;67(7):624-631.
68. Linssen AM, Vuurman EF, Sambeth A, etal. Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate. Psychopharmacology (Berl). 2011;218(3): 533-542.
69. Linssen AMW. Cognitive and Electrophysiological Responses to Dopaminergic Manipulations. Maastricht, The Netherlands: Maastricht University Department of Psychology and Neuroscience; 2012.
70. Kratz O, Studer P, Baack J, etal. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the attention network test. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):81-89.
71. Linssen AM, Vuurman EF, Sambeth A, Riedel WJ. Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers. Psychopharmacology (Berl). 2012;221(4):611-619.
72. Ogrim G, Hestad KA, Brunner JF, Kropotov J. Predicting acute side effects of stimulant medication in pediatric attention deficit/hyperactivity disorder: data from quantitative electroencephalography, event-related potentials, and a continuous-performance test. Neuropsychiatr Dis Treat. 2013;9:1301-1309.
73. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics. 1991;87(4):519-531.
74. Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1995;34(7):886-896.
75. Kaufman J, Birmaher B, Brent D, et al. Kiddie-SADS (PL) Schedule for Affective Disorders and Schizophrenia-Present-Life Version for School Aged Children (6-18 Years). J Am Accad Child Adolec Psychiatry. 1997;36:980-988.
76. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The development and well-being assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. J Child Psychol Psychiatry. 2000;41(5):645-655.
77. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268.
78. Gioia GA, Isquith PK. BRIEF behavior rating inventory of executive function. Psychological Assessment Resources Inc. 2000.
79. Mueller A, Candrian G, Kropotov JD, Ponomarev VA, Baschera GM. Classification of ADHD patients on the basis of independent ERP components using a machine learning system. Nonlinear Biomed Phys. 2010;4 Suppl 1:S1.
80. Mueller A, Candrian G, Grane VA, Kropotov JD, Ponomarev VA, Baschera GM. Discriminating between ADHD adults and controls using independent ERP components and a support vector machine: a validation study. Nonlinear Biomed Phys. 2011;5:5.
81. Kropotov JD, Ponomarev VA. Decomposing N2 NOGO wave of event-related potentials into independent components. Neuroreport. 2009;20(18):1592-1596.
82. Clarke AR, Barry RJ, Heaven PC, McCarthy R, Selikowitz M, Byrne MK. EEG coherence in adults with attention-deficit/hyperactivity disorder. Int J Psychophysiol. 2008;67(1):35-40.
83. Brandeis D, van LeeuwenTH, Steger J, Imhof K, Steinhausen HC. Mapping brain functions of ADHD children. International Congress Series. 2002;1232:649-654.
84. Coull JT, Frith CD, Dolan RJ, Frackowiak RS, Grasby PM. The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Eur J Neurosci. 1997;9(3):589-598.
85. Coull JT, Buchel C, Friston KJ, Frith CD. Noradrenergically mediated plasticity in a human attentional neuronal network. Neuroimage. 1999;10(6):705-715.
86. Beste C, Willemssen R, Saft C, Falkenstein M. Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects. Neuropsychologia. 2010;48(2):366-373.
87. Kropotov JD. Quantitative EEG Event-Related Potentials and Neurotherapy. Amsterdam, The Netherlands: Elsevier AP; 2009.
88. Clarke AR, Barry RJ, Dupuy FE, McCarthy R, Selikowitz M, Johnstone SJ. Excess beta activity in the EEG of children with attention-deficit/hyperactivity disorder: a disorder of arousal?. Int J Psychophysiol. 2013;89(3):314-319.
89. Stuss DT, Alexander MP, Shallice T, etal. Multiple frontal systems controlling response speed. Neuropsychologia. 2005;43(3):396-417.